AriBio’s oral Alzheimer’s drug meets monotherapy goal in ph. 3
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial.
AriBio is a clinical-stage South Korean biopharmaceutical company developing oral therapies for neurodegenerative and inflammatory disease, with U.S. clinical operations in San Diego. Its lead candidate AR1001 (mirodenafil) is in global Phase 3 development for early Alzheimer's disease.
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial.
Chairman and Chief Executive Officer